QHSLab, Inc. Files Q3 2024 10-Q
Ticker: USAQ · Form: 10-Q · Filed: Nov 13, 2024 · CIK: 856984
Sentiment: neutral
Topics: 10-Q, quarterly-report, medical-instruments
TL;DR
QHSLab filed its Q3 10-Q. Check financials.
AI Summary
QHSLab, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as USA EQUITIES CORP. and AMERICAN BIOGENETIC SCIENCES INC, is incorporated in Nevada and operates in the Surgical & Medical Instruments & Apparatus sector. Its principal executive offices are located in West Palm Beach, Florida.
Why It Matters
This filing provides investors with an update on QHSLab, Inc.'s financial performance and operational status for the third quarter of 2024.
Risk Assessment
Risk Level: low — This is a routine quarterly filing with no immediate red flags or significant new information presented.
Key Numbers
- 20240930 — Reporting Period End Date (Indicates the end of the fiscal quarter being reported.)
- 20241113 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- QHSLab, Inc. (company) — Filer
- USA EQUITIES CORP. (company) — Former company name
- AMERICAN BIOGENETIC SCIENCES INC (company) — Former company name
- West Palm Beach, Florida (location) — Business address
- September 30, 2024 (date) — Reporting period end date
FAQ
What is the primary business of QHSLab, Inc.?
QHSLab, Inc. operates in the Surgical & Medical Instruments & Apparatus sector, with SIC code 3841.
When does QHSLab, Inc.'s fiscal year end?
QHSLab, Inc.'s fiscal year ends on December 31st.
What were the previous names of QHSLab, Inc.?
QHSLab, Inc. was formerly known as USA EQUITIES CORP. and AMERICAN BIOGENETIC SCIENCES INC.
Where is QHSLab, Inc. headquartered?
QHSLab, Inc.'s business address is located at 901 NORTHPOINT PARKWAY, SUITE 302, WEST PALM BEACH, FL 33407.
For which reporting period is this 10-Q filing?
This 10-Q filing is for the period ending September 30, 2024.
Filing Stats: 4,396 words · 18 min read · ~15 pages · Grade level 16.2 · Accepted 2024-11-13 14:12:49
Key Financial Figures
- $0.0001 — nge on Which Registered Common Stock, $0.0001 Par Value USAQ NA Indicate by che
Filing Documents
- form10-q.htm (10-Q) — 656KB
- ex31.htm (EX-31) — 11KB
- ex32.htm (EX-32) — 8KB
- 0001493152-24-045058.txt ( ) — 3754KB
- usaq-20240930.xsd (EX-101.SCH) — 30KB
- usaq-20240930_cal.xml (EX-101.CAL) — 40KB
- usaq-20240930_def.xml (EX-101.DEF) — 132KB
- usaq-20240930_lab.xml (EX-101.LAB) — 241KB
- usaq-20240930_pre.xml (EX-101.PRE) — 200KB
- form10-q_htm.xml (XML) — 523KB
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION ITEM 1.
FINANCIAL STATEMENTS
FINANCIAL STATEMENTS. 4 ITEM 2.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. 19 ITEM 4.
CONTROLS AND PROCEDURES
CONTROLS AND PROCEDURES. 23
- OTHER INFORMATION
PART II - OTHER INFORMATION ITEM 6. EXHIBITS. 24 2 Cautionary Note Regarding Forward-Looking Statements This report contains forward-looking statements. Certain of the matters discussed herein concerning, among other items, our operations, cash flows, financial position and economic performance including, in particular, future sales, product demand, competition and the effect of economic conditions, include forward-looking statements. Forward-looking "anticipates," "intends," "plans," "believes," "estimates" and similar expressions. Although we believe that the forward-looking statements contained in this report are based upon reasonable assumptions, these statements and other projections contained herein expressing opinions about future outcomes and non-historical information, are subject to uncertainties and, therefore, there is no assurance that the outcomes expressed in these statements will be achieved. Investors are cautioned that forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from the expectations expressed in forward-looking statements contained herein. Given these uncertainties, you should not place any reliance on these forward-looking statements which speak only as of the date hereof. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. You are advised, however, to consult any additional disclosures we make in our reports filed with the Securities and Exchange Commission ("SEC"). 3 PART I – FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS (unaudited) Condensed Consolidated Balance Sheets – September 30, 2024 (unaudited) and December 31, 2023 5 Condensed Consolida